The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
Joel Simrén(University of Gothenburg), Nicholas J. Ashton(King's College London), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Niklas Mattsson(Malmö University), Antoine Leuzy(Banner Sun Health Research Institute), Andréa Lessa Benedet(University of Pittsburgh), Oskar Hansson(Eli Lilly (United States)), Bruno Vellas(Centre Hospitalier Universitaire de Toulouse), Abdul Hye(King's College London), Iwona Kłoszewska(Medical University of Lodz), Dag Aarsland(King's College London), Thomas K. Karikari(University of Pittsburgh), Magda Tsolaki(Aristotle University of Thessaloniki), Michael Schöll(Wallenberg Wood Science Center), Henrik Zetterberg(University of Wisconsin–Madison), Hilkka Soininen(University of Eastern Finland), Eric Westman(Wellcome Centre for Human Neuroimaging), Simon Lovestone(Royal Buckinghamshire Hospital), Pedro Rosa‐Neto(Center for Diagnosis and Research on Alzheimer's Disease), Patrizia Mecocci(University of Perugia)
Cited by 354
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k